The US authorities’s funding will see as much as 100,000 doses delivered “towards the end of 2020”, with the choice for an additional a million doses subsequent 12 months, AstraZeneca mentioned.
The firm is enrolling 6,100 contributors in two separate testing regimes of the “long-acting antibody (LAAB)” mixture therapy within the United States and different nations, beginning “in the next weeks”.
One will consider its security and efficacy “to prevent infection for up to 12 months” and includes round 5,000 contributors, the corporate mentioned in an announcement to the London Stock Exchange.
The second will consider post-exposure prophylaxis and pre-emptive therapy in roughly 1,100 contributors, it added.
AstraZeneca mentioned it’s also planning extra trials to judge the drug in roughly 4,000 sufferers for the therapy of Covid-19.
“This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections,” chief government Pascal Soriot mentioned.